Sabiad
Sabiad BV is a pioneering company focused on developing advanced theranostic solutions for bacterial infections, especially Staphylococcus aureus. Founded in 2022 as a spin-off from the University Medical Center Groningen, the company aims to revolutionize infection management through precision diagnostics and targeted therapies, reducing reliance on antibiotics and combating antimicrobial resistance. Their innovative platform, StaphMark, utilizes the 1D9 antibody for real-time detection and treatment of bacterial infections, integrating diagnostics and therapeutics for personalized patient care.
Industries
Nr. of Employees
small (1-50)
Products
Targeted antibody-based theranostic platform for Staphylococcus aureus
A theranostic platform that uses a fully human monoclonal antibody tracer to enable specific detection (PET and NIR fluorescence) and localized therapeutic interventions (photodynamic therapy) for S. aureus infections.
Point-of-care synovial fluid and nasal swab diagnostic prototype
Near-market prototype for rapid detection of S. aureus in synovial fluid and nasal swabs using antibody-based bioluminescence assays, developed and validated in collaboration with clinical partners.
Targeted antibody-based theranostic platform for Staphylococcus aureus
A theranostic platform that uses a fully human monoclonal antibody tracer to enable specific detection (PET and NIR fluorescence) and localized therapeutic interventions (photodynamic therapy) for S. aureus infections.
Point-of-care synovial fluid and nasal swab diagnostic prototype
Near-market prototype for rapid detection of S. aureus in synovial fluid and nasal swabs using antibody-based bioluminescence assays, developed and validated in collaboration with clinical partners.
Services
Theranostic agent research and development
R&D services to design and develop integrated diagnostic and therapeutic antibody-based agents for bacterial infections.
Point-of-care diagnostic development and validation
Development and clinical validation of rapid ex vivo tests for synovial fluid and nasal swabs using antibody-based bioluminescence assays, advancing prototypes toward near-market TRL.
Preclinical imaging and efficacy testing
Preclinical evaluation of imaging tracers and therapeutic conjugates in animal infection models, including multimodal imaging to guide surgical strategies.
Clinical validation support and partner coordination
Coordination with hospitals and clinical partners to run retrospective and prospective sample testing, publication, and dissemination activities.
Theranostic agent research and development
R&D services to design and develop integrated diagnostic and therapeutic antibody-based agents for bacterial infections.
Point-of-care diagnostic development and validation
Development and clinical validation of rapid ex vivo tests for synovial fluid and nasal swabs using antibody-based bioluminescence assays, advancing prototypes toward near-market TRL.
Preclinical imaging and efficacy testing
Preclinical evaluation of imaging tracers and therapeutic conjugates in animal infection models, including multimodal imaging to guide surgical strategies.
Clinical validation support and partner coordination
Coordination with hospitals and clinical partners to run retrospective and prospective sample testing, publication, and dissemination activities.
Expertise Areas
- Theranostics for bacterial infections
- Antibody-based targeting and tracer development
- Molecular imaging (PET and NIR fluorescence)
- Point-of-care diagnostic development
Key Technologies
- Monoclonal antibody tracers for bacterial targeting
- Zirconium-89 radiolabeling for PET imaging
- Near-infrared (NIR) fluorescent labeling
- Bioluminescence-based point-of-care assays